Haemonetics (HAE) Tops Q4 EPS by 6c, Offers FY Guidance

Haemonetics (NYSE: HAE) reported Q4 EPS of $0.65, $0.06 better than the analyst estimate of $0.59. Revenue for the quarter came in at $265 million versus the consensus estimate of $257.82 million.

GUIDANCE:

Haemonetics sees FY2023 EPS of $2.50-$2.90, versus the consensus of $2.53.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance